Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)

Inclusion Criteria:

• Male or female, 18 to 55 years of age
• Diagnosed with relapsing multiple sclerosis, with at least one relapse in the last two years
• Females must not plan on becoming pregnant
• Females must either be post-menopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control and willing to continue birth control until 30 days after the last dose of study drug
• Males must not intend to impregnate a partner during the study or for 30 days after the study and must also practice acceptable birth control with their partners

Exclusion Criteria:

• Significant long-lasting disease of the immune system other than multiple sclerosis
• Past or current medical disease (heart, liver, kidney, etc.) including severe asthma, cancer or advancing brain or spinal cord disorder
• Known or suspected long-lasting infectious disease including HIV, hepatitis B, or hepatitis C
• Treatment with certain steroid or hormone medications within 30 days before the pre-study MRI scan
• Treatment with other medications that suppress the immune system within 6 months before the pre-study MRI scan
• Certain treatments and medications are not allowed
• Laboratory and other tests will be performed to determine further eligibility
• History of drug or alcohol abuse in the last year
• History of medical or psychiatric condition that could pose a risk for participation in the study
• Females who are pregnant or breast feeding
• Participation in any other trial of an investigational agent within 90 days before the start of the study
• History of not following instructions with past therapy.